Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Rocket Pharmaceuticals, Inc. (RCKT) had Normalized Income after Taxes of $-47.59M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-47.59M |
|
-- |
|
-- |
|
$48.51M |
|
$-48.51M |
|
$0.92M |
|
$-47.59M |
|
$-47.59M |
|
$-47.59M |
|
$-47.59M |
|
$-47.59M |
|
|
Normalized Income after Taxes |
$-47.59M |
$-48.51M |
|
$-46.37M |
|
112.13M |
|
112.13M |
|
$-0.42 |
|
$-0.42 |
|
| Balance Sheet Financials | |
$149.83M |
|
$26.66M |
|
$135.58M |
|
$285.41M |
|
$24.47M |
|
$19.35M |
|
$22.90M |
|
$47.37M |
|
$238.04M |
|
$173.74M |
|
$238.04M |
|
109.12M |
|
| Cash Flow Statement Financials | |
$-45.39M |
|
$17.45M |
|
$-0.00M |
|
$78.90M |
|
$50.95M |
|
$-27.95M |
|
$8.49M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.12 |
|
-- |
|
-- |
|
0.08 |
|
0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-45.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.99% |
|
-27.39% |
|
-16.68% |
|
-18.49% |
|
$2.18 |
|
$-0.41 |
|
$-0.40 |
|